As of November 14, 2026, SAB Biotherapeutics, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on January 7, 2026 (Form 8-K, January 7, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like SAB Biotherapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
SAB Biotherapeutics, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-01-07. Every row below is cited to the filing it comes from, and this page adds each new change as SAB Biotherapeutics, Inc. files it.
Also on the record for SAB Biotherapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 14, 2026 | Stake report, Schedule 13G/A, by BALYASNY ASSET MANAGEMENT L.P. | 9.45% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Caligan Partners LP | 8.8% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Commodore Capital LP | 9.9% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Perceptive Advisors LLC | 7.3% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Vivo Opportunity Fund Holdings, L.P. | 9.99% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Woodline Partners LP | 6.8% of the class | 5%+ stakes | Source |
| August 12, 2026 | Stake report, Schedule 13G, by Adage Capital Management, L.P. | 8.38% of the class | 5%+ stakes | Source |
| August 10, 2026 | Stake report, Schedule 13D/A, by RA Capital Management, L.P. | 9.9% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by Balyasny Asset Management L.P. | 9.99% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by Caligan Partners LP | 10.4% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Perceptive Advisors LLC | 8.4% of the class | 5%+ stakes | Source |
| May 1, 2026 | Stake report, Schedule 13G, by Millennium Management LLC | 5.1% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs SAB Biotherapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on SAB Biotherapeutics, Inc. and the records around it.
SAB Biotherapeutics, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Form D filing Aug 2025
- Who owns it
Companies that share a holder
- Caligan Partners LP also filed stake reports on 9 other companies: Avalo Therapeutics, Inc. (Aug 2026), Cellectar Biosciences, Inc. (Aug 2026), Faeth Therapeutics, Inc. (Aug 2026)
- Woodline Partners LP also filed stake reports on 19 other companies: Biohaven Ltd. (Aug 2026), Black Rock Coffee Bar, Inc. (Aug 2026), CalciMedica, Inc. (Aug 2026)
- Vivo Opportunity Fund Holdings, L.P. also filed stake reports on 20 other companies: ArriVent BioPharma, Inc. (Oct 2026), Clene Inc. (Aug 2026), Compass Therapeutics, Inc. (Aug 2026)
Watch SAB Biotherapeutics, Inc.
Get an email when SAB Biotherapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on SAB Biotherapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on SAB Biotherapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on SAB Biotherapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 23 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-01-07 | Reported | not named in the filing | 8-K, 2026-01-07 |
New leaders reset buying decisions — get the Full Report on SAB Biotherapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at SAB Biotherapeutics, Inc., with the record behind each one.
Find candidates like senior executive at SAB Biotherapeutics, Inc.Every change, in the filing's words
Reported
On January 5, 2026, the Board of Directors (the "Board") of SAB Biotherapeutics, Inc., a Delaware corporation (the "Company"), following the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed, David Zaccardelli, Pharm.D, and Rita Jain, M.D. each to serve as a Class II director of the Company, effective January 5, 2026, and to serve until the Company's 2026 annual meeting of stockholders or until their respective successors are duly elected and qualified.
- Dr. Zaccardelli will act as Chairperson of the Board.
- Samuel J. Reich, the Company's Chief Executive Officer and former Chairperson, will continue to serve as a member of the Board.
- Each of Dr. Jain and Dr. Zaccardelli were appointed to the Board at the recommendation of RA Capital Healthcare Fund, L.P. ("RA Capital") pursuant to the letter agreement entered into between the Company and RA Capital dated July 21, 2025 in connection with the Company's July 2025 private placement of securities.
- Each of Dr. Zaccardelli or Dr. Jain will receive compensation similar to the other non-employee members of the Board as described in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as filed with the Securities and Exchange Commission on March 31, 2025 (the "Annual Report"), as such compensation may be amended from time to time.
- David Zaccardelli, Pharm.D., served as the President, Chief Executive Officer and member of the board of directors of Verona Pharma plc from February 2020 until its acquisition by Merck in October 2025.
- From 2018 until its acquisition by Swedish Orphan Biovitrum AB ("Sobi") in November 2019, Dr. Zaccardelli served as President and CEO and on the board of directors of Dova Pharmaceuticals, a U.S. company developing therapeutics for rare diseases.
Tools for this story
Each opens in a new tab, filled in for SAB Biotherapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
